Phaseline

Companies › Takeda

Takeda: clinical trials, targets and expected readouts

35 active drug programs in 164 registered trials: 77 Phase 2, 50 Phase 3, 21 Phase 4, 16 Phase 1; Oncology, Immunology, Hematology, Neurology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Vedolizumab
Integrin alpha-4/beta-7 inhibitor
ITGA4, ITGB7Phase 4Ulcerative Colitis; Crohn's Disease; Crohn's Disease (CD); Moderately to Severely Active Ulcerative Colitis …May 2027
Tofacitinib
Janus Kinase (JAK) inhibitor
JAK3, JAK1, JAK2, TYK2Phase 4Ulcerative Colitis; Rheumatoid Arthritis; Axial Spondyloarthritis; Oral Lichen Planus …Jul 2027
Fruquintinib
Vascular endothelial growth factor receptor inhibitor
FLT1, FLT4, KDRPhase 4Colorectal CancerOct 2027
Replagal
alpha-galactosidase A (agalsidase alfa) enzyme replacement therapy
GLAPhase 4Fabry DiseaseOct 2027
Brentuximab Vedotin
Tubulin inhibitor; Tumor necrosis factor receptor superfamily member 8 binding agent
Tubulin, TNFRSF8Phase 4Hodgkin Lymphoma; Lymphoma; Hodgkin Disease; Ann Arbor Stage III Hodgkin Lymphoma …Dec 2027
TAK-861
Histamine H3 receptor antagonist
–Phase 3Narcolepsy Type 1 (NT1); Narcolepsy Type 1Dec 2026
Tetravalent Dengue Vaccine (TDV), new formulation (TAK-003)
Live attenuated tetravalent dengue virus vaccine
–Phase 3Dengue FeverDec 2026
Maribavir
Serine/threonine-protein kinase BGLF4 inhibitor; Phosphotransferase pUL97 inhibitor
UL97Phase 3Cytomegalovirus (CMV); Hematologic MalignancyJan 2027
Zasocitinib
TEC kinase inhibitor
TEC, ZAP70Phase 3Psoriatic Arthritis; Plaque Psoriasis; Hidradenitis Suppurativa; Nonsegmental Vitiligo …Feb 2027
Teduglutide
Glucagon-like peptide 2 receptor agonist
GLP2RPhase 3Short Bowel SyndromeFeb 2027
TAK-279–Phase 3Plaque Psoriasis; Crohn's Disease; Ulcerative ColitisFeb 2027
Apadamtase Alfa (TAK-755)
A disintegrin and metalloproteinase with thrombospondin motifs 13 exogenous protein
ADAMTS13Phase 3Thrombotic Thrombocytopenic Purpura (TTP); Acute Ischemic StrokeMar 2027
Ponatinib
Bcr/Abl fusion protein inhibitor
ABL1, BCRPhase 3Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL); Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive); B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative; Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive …Jul 2027
Vonicog Alfa
von Willebrand factor exogenous protein
VWFPhase 3Von Willebrand Disease (VWD)Nov 2027
Elritercept
Erythropoietin receptor agonist
EPORPhase 3Myelodysplastic Syndromes; Myelodysplastic Syndrome; MyelofibrosisFeb 2028
Mezagitamab (TAK-079)
Lymphocyte differentiation antigen CD38 binding agent
CD38Phase 3Immune Thrombocytopenic Purpura (ITP); Kidney Disease; Antibody-Mediated Rejection (AMR)Mar 2028
TAK-881
Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (r
–Phase 3Primary Immunodeficiency Diseases (PID); Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)May 2028
Fazirsiran
Z-AAT reducing agent; inhibits expression of Z-AAT protein
SERPINA1Phase 3Alpha1-Antitrypsin DeficiencyAug 2028
TAK-330
Factor Xa inhibitor reversal agent (recombinant human Factor Xa)
F10Phase 3Coagulation DisorderAug 2028
IGI, 10% (Gammagard Liquid, TAK-339, KIOVIG)
Immune globulin infusion (human), 10% IV
–Phase 3Multiple MyelomaSep 2028
TAK-928–Phase 3IO Resistant Squamous and Nonsquamous NSCLCNov 2028
Vortioxetine
Serotonin 1a (5-HT1a) receptor agonist; Serotonin transporter inhibitor; Serotonin 3a (5-HT3a) receptor antagonist
HTR1A, SLC6A4, HTR3APhase 3Major Depressive Disorder; Glioblastoma; DepressionSep 2029
TDV (QDENGA, TAK-003)
Tetravalent live attenuated dengue virus vaccine
–Phase 3Dengue FeverMar 2030
Mobocertinib
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 3Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC); Non-Small Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung–
TAK-360
Orexin receptor agonist
HCRTPhase 2Idiopathic Hypersomnia; Narcolepsy Type 2; Narcolepsy Type 1Nov 2026
Rusfertide
Hepcidin mimetic
HAMPPhase 2Polycythemia VeraOct 2027
TAK-411
Hypersialylated Immune Globulin G with immunomodulatory properties
–Phase 2Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)Dec 2027
TAK-226
Erythropoietin receptor agonist
EPORPhase 2Myelodysplastic SyndromesJun 2028
Elaprase
Iduronate-2-sulfatase (IDS) enzyme replacement therapy administered intravenously
IDSPhase 2Hunter SyndromeJan 2029
Idursulfase-IT
Iduronate-2-sulfatase (IDS) enzyme replacement therapy administered intrathecally
IDSPhase 2Hunter SyndromeJan 2029
TAK-007
CAR-T cell therapy
–Phase 2Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)Dec 2038
Mirvetuximab Soravtansine (TAK-853)
Folate receptor alpha binding agent; Tubulin inhibitor
FOLR1, TubulinPhase 1Ovarian CancerMar 2027
TAK-781–Phase 1Healthy VolunteersApr 2028
TAK-188
CCR8 antagonist targeting regulatory T cells (Tregs)
CCR8Phase 1Advanced or Metastatic Solid TumorsDec 2028
TAK-505–Phase 1Malignant Solid TumorsAug 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT02758717Brentuximab VedotinPhase 2Ann Arbor Stage IB Hodgkin LymphomaOncologyAug 2019
NCT03807778MobocertinibPhase 1Non-Small Cell Lung CancerOncologyNov 2021
NCT04925973TofacitinibPhase 2Ulcerative Colitis AcuteImmunologyDec 2023
NCT04496960TofacitinibPhase 1Sjogren's SyndromeImmunologyJan 2025
NCT03976245TofacitinibPhase 4Rheumatoid ArthritisImmunologyMar 2025
NCT06112665TofacitinibPhase 4Axial SpondyloarthritisImmunologyMar 2025
NCT07044141TofacitinibPhase 1VitiligoImmunologySep 2025
NCT05595447Brentuximab VedotinPhase 2Hodgkin LymphomaOncologyOct 2025
NCT04743518VedolizumabPhase 4Ulcerative ColitisImmunologyDec 2025
NCT02734771Brentuximab VedotinPhase 2Diffuse Large B-Cell LymphomaOncologyDec 2025
NCT04743518TofacitinibPhase 4Ulcerative ColitisImmunologyDec 2025
NCT05481619VedolizumabPhase 4Ulcerative ColitisImmunologyJan 2026
NCT06317220VedolizumabPhase 2Collagenous GastritisGastroenterologyFeb 2026
NCT06756152VedolizumabPhase 2Biphenotypic Acute LeukemiaOncologyJul 2026
NCT07554820TofacitinibPhase 4Rheumatoid ArthritisCardiovascularAug 2026
NCT04129502MobocertinibPhase 3Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)OncologySep 2026
NCT02716116MobocertinibPhase 1Carcinoma, Non-Small-Cell LungOncologySep 2026
NCT03819296VedolizumabPhase 1Clinical Stage 0 Cutaneous Melanoma AJCC v8OncologyOct 2026
NCT03517137Brentuximab VedotinPhase 2Advanced Hodgkin LymphomaOncologyNov 2026
NCT06812078TAK-360Phase 2Idiopathic HypersomniaNeurologyNov 2026
NCT06952699TAK-360Phase 2Narcolepsy Type 2NeurologyNov 2026
NCT06207123PonatinibPhase 1Acute LeukemiaOncologyDec 2026
NCT07363720TAK-861Phase 3Narcolepsy Type 1 (NT1)NeurologyDec 2026
NCT07047521Tetravalent Dengue Vaccine (TDV), new formulation (TAK-003)Phase 3Dengue FeverInfectious diseaseDec 2026
NCT06841705VedolizumabPhase 2Immune Checkpoint Inhibitor-Related ColitisImmunologyDec 2026
NCT05180097Brentuximab VedotinPhase 2Hodgkin LymphomaOncologyDec 2026
NCT05814640VortioxetinePhase 1DepressionPsychiatryDec 2026
NCT07131813TofacitinibPhase 4Oral Lichen PlanusGastroenterologyJan 2027
NCT05319353MaribavirPhase 3Cytomegalovirus (CMV)Infectious diseaseJan 2027
NCT05357794Brentuximab VedotinPhase 2Mycosis FungoidesOncologyJan 2027
NCT03739814PonatinibPhase 2B Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeOncologyFeb 2027
NCT07244263ZasocitinibPhase 2Hidradenitis SuppurativaImmunologyFeb 2027
NCT06973304TeduglutidePhase 3Short Bowel SyndromeGastroenterologyFeb 2027
NCT03356054Brentuximab VedotinPhase 1DLBCLOncologyFeb 2027
NCT06233461TAK-279Phase 2Crohn's DiseaseImmunologyFeb 2027
NCT03057795Brentuximab VedotinPhase 2Classic Hodgkin LymphomaOncologyFeb 2027
NCT03147612PonatinibPhase 2Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveOncologyFeb 2027
NCT04683003Apadamtase Alfa (TAK-755)Phase 3Thrombotic Thrombocytopenic Purpura (TTP)ImmunologyMar 2027
NCT06390995Mirvetuximab Soravtansine (TAK-853)Phase 1Ovarian CancerOncologyMar 2027
NCT07108283ZasocitinibPhase 2Nonsegmental VitiligoImmunologyMar 2027
NCT03907488Brentuximab VedotinPhase 3Ann Arbor Stage III Hodgkin LymphomaOncologyMar 2027
NCT06475820VedolizumabPhase 2Acute Lymphoblastic LeukemiaOncologyApr 2027
NCT06579755Tetravalent Dengue Vaccine (TDV), new formulation (TAK-003)Phase 3Dengue FeverInfectious diseaseApr 2027
NCT06377566Brentuximab VedotinPhase 2Hodgkin LymphomaOncologyApr 2027
NCT07313072TofacitinibPhase 2Nail PsoriasisImmunologyApr 2027
NCT03113500Brentuximab VedotinPhase 2Adult T-Cell Leukemia/LymphomaOncologyApr 2027
NCT06581328VedolizumabPhase 4Ulcerative ColitisImmunologyMay 2027
NCT06581328VedolizumabPhase 4Ulcerative ColitisImmunologyMay 2027
NCT03007030Brentuximab VedotinPhase 2CD30-Positive Neoplastic Cells PresentOncologyMay 2027
NCT06671496ZasocitinibPhase 3Psoriatic ArthritisImmunologyMay 2027
NCT06671483ZasocitinibPhase 3Psoriatic ArthritisImmunologyMay 2027
NCT03712202Brentuximab VedotinPhase 2Ann Arbor Stage I Hodgkin LymphomaOncologyMay 2027
NCT05845723TofacitinibPhase 2AneurysmCardiovascularJun 2027
NCT06227910VedolizumabPhase 3Crohn's DiseaseImmunologyJun 2027
NCT06698822TofacitinibPhase 2Cutaneous T-Cell LymphomaOncologyJun 2027
NCT06045754VedolizumabPhase 4Crohn's DiseaseImmunologyJun 2027
NCT01896999Brentuximab VedotinPhase 1Recurrent Classic Hodgkin LymphomaOncologyJun 2027
NCT06498089TofacitinibPhase 4Takayasu ArteritisImmunologyJun 2027
NCT03233347Brentuximab VedotinPhase 2Ann Arbor Stage I Hodgkin LymphomaOncologyJul 2027
NCT06095128VedolizumabPhase 4Ulcerative ColitisImmunologyJul 2027

The 60 nearest readouts of 164 trials; the rest in the app.

From the company's SEC filings

Cash and short-term investments of 536.5bn JPY on 2025-03-31; operating cash flow positive

Complete response letters from FDA

Specialist investors

Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

Tubulin (2) IDS (2) EPOR (2) ADAMTS13 (1) CD38 (1) ITGA4 (1) ITGB7 (1) TNFRSF8 (1) JAK3 (1) JAK1 (1) JAK2 (1) TYK2 (1)

Companies with the same targets

Roche Sichuan Kelun-Biotech Biopharmaceutical Pfizer GSK AbbVie RemeGen Fidia Farmaceutici Beijing Biostar Pharmaceuticals Urotronic Ambrx

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.